Matt Gline, Roivant CEO (John Sciulli/Getty Images for GLG)

As Roivant read­ies for a UC clash with Mer­ck, CEO Matt Gline is can­did about keep­ing a com­pet­i­tive edge

Roivant CEO Matt Gline is get­ting ready for a de­vel­op­ment show­down with Mer­ck and its new­ly ac­quired ul­cer­a­tive col­i­tis drug from Prometheus Bio­sciences.

On Thurs­day, Roivant re­leased new Phase IIb da­ta for RVT-3101, the UC pro­gram it ac­quired from Pfiz­er late last year, show­ing that the drug’s ef­fects could be main­tained for up to a year. It’s con­fir­ma­tion of ear­li­er da­ta show­ing suc­cess at 14 weeks — a sta­tis­ti­cal­ly sig­nif­i­cant find­ing, Roivant said in Jan­u­ary.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.